Aurora B kinase (AURKB) and epidermal growth factor receptor 1 (EGFR) belong to serine/threonine and tyrosine kinase family of proteins. Both these kinases are found to overexpress in a large number of epithelial cancers, including hormonal refractory prostate cancer. In this communication, we present evidence for down-regulated expression of AURKB and EGFR, either alone or in combination, in prostate cancer cells. The results show that AURKB and EGFR were efficiently down-regulated in a dose-dependent manner. AURKB and EGFR siRNA in combination have shown enhanced therapeutic effect by inhibiting PC3 cell proliferation and inducing apoptosis in vitro, whereas androgen-dependent cancer cells LNCaP remain unaffected correlating the endogenous expression levels. Knockdown of AURKB and EGFR individually resulted in inhibition of prostate tumor growth in athymic nude mice and their combined knockdown resulted in tumor regression in which 40% of the treated mice were found to be tumor free, implicating the potential therapeutic benefits of AURKB-EGFR combination therapy.
Introduction
Prostate cancer is the second most leading cause of cancer deaths in men after lung cancer. At present, B85% of newly diagnosed prostate cancers are limited to prostate. 1 Complete surgical resection, radiotherapy, or their combination is the only potentially curative treatment option for patients with localized prostate cancer. 2 However, majority of patients with relapsed or metastasized prostate tumors initially respond to androgen ablation treatment. But once the patient stops responding to the first line of hormonal therapy, therapeutic options become limited and survival is in the order of 6-12 months, as prostate cancer becomes refractory to hormonal treatment. The progression of prostate cancer from androgen dependent to refractory is a multi-step process involving changes in functions of different growth signals. 3 In addition, the chromosomal instability leading to the generation of numerical and structural changes has also been implicated in the pre-neoplastic and neoplastic stages of prostate cancer. 4 Although the molecular events associated with chromosomal instability are not fully understood, it is associated with aberrant expression of proteins such as the Aurorakinase family of proteins. 4 Aurora kinases, a family of serine/threonine kinases, have an important regulatory function from G2 to cytokinesis, encompassing important cell-cycle events such as centrosome duplication, chromosome bi-orientation, and segregation. Inappropriate expression of these kinases is shown to induce aberrant mitosis and centrosome irregularities, which lead to anueploidy and cell transformation. The aurora kinase family includes genes Aurora A, Aurora B, and Aurora C. Of these, Aurora B kinase (AURKB) is a multi-functional chromosomal passenger protein, localized on the centromeres from prophase through the metaphase-anaphase transition. 5 Analysis of prostate patient samples revealed overexpression of AURKB in androgen-independent cancers rather than androgen-dependent cancers. 6 Furthermore, AURKB-transfected cells have an unstable chromosome number and show aggressive tumor phenotype. 7 These observations correlate well with in vitro studies in which AURKB was found to be vigorously expressed in androgen-independent prostate cancer cell lines (PC3 and DU145), whereas a mild expression was observed in the androgen-sensitive cell lines (LNCaP and EPN). 8 Similarly, in hormone refractory prostate cancers, a number of growth factor receptors such as androgen receptor and epidermal growth factor receptor 1 (EGFR) are found to overexpress, driving cancer cell proliferation and metastasis. 9 A functional cross-talk between growth factors and their receptors (androgen receptor and EGFR family) are also found to have an important function in progression of androgen-independent prostate cancer. In addition, earlier studies have suggested that the EGFR-driven autocrine pathway does also have an important function in hormone refractory prostate cancers. 10 As AURKB and EGFR are found to overexpress in hormonal refractory prostate cancer, 8, 9 a number of studies have been carried out to determine the potential therapeutic benefits of their inhibition (by small molecule inhibitors), either alone or in combination, with cytotoxic chemotherapeutic drugs. 6, 10, 11 However, most of these inhibitors show non-specificity towards other kinases. In addition, these inhibitors are aimed at only a specific domain of the protein leaving noninhibitor domains remain functional. Thus, applications of small molecule inhibitors have limitations to understand the therapeutic benefits of combination therapies.
RNA interference (RNAi) is a new form of antisense gene therapy, 12 wherein the possibility of multiple gene knockdowns can be performed simultaneously to explore the potential therapeutic combinations, which may have synergistic effect. In this report, we examined the hypothesis that the knockdown of AURKB and EGFR simultaneously may have synergistic anti-tumor activities. We used siRNA against AURKB as well as EGFR and determined their efficacy, both in vitro and in vivo, either alone or in combination. Both these proteins show highest expression levels in PC3 and least in LNCaP cell lines.
Results

siRNA26 and siRNA28 reduce AURKB and EGFR expression
To determine whether RNAi induction may specifically be useful for inhibition of AURKB and EGFR proteins, we generated three siRNAs each, targeting various regions of the aurkB and egfr genes. Transient transfection of these siRNA molecules to PC3 cells (transfection efficiency was 90 ± 6 and 85 ± 8%, respectively, for PC3 and LNCaP cells as determined from Cy-3-labeled siRNA) has resulted in significant reduction of corresponding mRNA levels. Of these siRNA molecules, siRNA26 for AURKB and siRNA28 for EGFR showed highest efficacy in knocking down their respective genes (Supplementary Figure 1A and B). Although siRNA26, siRNA28, and their combination showed maximum mRNA knockdown effect at the end of 48 h, by the end of 96 h, the expression levels of mRNA for both AURKB and EGFR were found to be restored to sub-normal levels (Supplementary Figure 2) .
Furthermore, neither siRNAs in combination with Hiperfect transfection reagent elicited interferon response (Supplementary Table 3 ; Supplementary Figure 3) . Hence, further experiments were carried out using siRNA26 for AURKB and siRNA28 for EGFR knockdown.
Protein blot analysis of PC3 cells have shown 77 ± 13% decrease in the protein expression levels of AURKB and 75 ± 10% of EGFR with either of the siRNAs, as detected by blot densitometry analysis. However, an AURKB-EGFR siRNA combination exhibited 56 ± 21% decrease in AURKB levels and 65±11% decrease in EGFR levels Combination of siRNA26 and siRNA28 results in greater apoptosis induction than either siRNA alone
To investigate whether the synergistic anti-proliferative effect was accompanied by an increase in apoptotic cell death, we examined the effect of AURKB and EGFR siRNA, either alone or in combination, in PC3 and LNCaP cells by quantifying the nucleosome fragments released at different time points. As shown in Figure 3a , the treatment of PC3 cells with a combination of siRNA26+28 has led to significant increase in the percent of cells undergoing apoptosis (P ¼ 9.46 Â 10 
Effect of combination of AURKB and EGFR on colonyforming efficiency of prostate cancer cells
The effect of knockdown of AURKB and EGFR either alone or in combination on anchorage-independent growth of PC3 cells was examined using the soft agar colony-forming assay. Both siRNA26 and siRNA28, either alone or in combination, were found to reduce the size and the number of colonies being formed when compared with control-siRNA-treated cells (Figure 4 ). The inhibition in colony formation and its size indicates that both AURKB and EGFR do have a significant function in cancer cell proliferation and anchorageindependent growth of hormone refractory prostate cancer cells.
In vivo protein knockdown efficacy of siRNA Combining siRNA26 with siRNA28 shows greater inhibition of tumor growth than each individually
Treatment of mice bearing subcutaneous PC3 prostate cancer xenografts with combination (siRNA26+28) has resulted in tumor regression (where P ¼ 0.0005), whereas either siRNA alone caused inhibition in tumor growth ( Figure 5) . Two of the five animals in the combination group were tumor free, whereas statistically significant Figure 5 Human prostate tumors xenografted in athymic Nude mice randomly segregated into four groups on reaching a size of 50-60 mm 3 . The animals were administered siRNA26, siRNA28, siRNA26+28, or control-siRNA complexed with Hiperfect transfection reagent intratumorally every week up to 4 weeks. siRNA26 (n ¼ 5), siRNA28 (n ¼ 3), and their combination (n ¼ 5) were found to show significant tumor growth regression from third week onward over the control-siRNA-treated animals (n ¼ 5); *represents significant tumor growth regression; (m) indicates day on which siRNA administered. Statistical significance was found at Pp0.05.
AURKB-EGFR knockdown shows enhanced therapeutic efficacy MK Addepalli et al tumor inhibition was observed in both siRNA26 (P ¼ 0.025) and 28 (P ¼ 0.026)-treated groups compared with control-siRNA group. The combination of siRNA26 and siRNA28 resulted in statistically greater tumor regression compared to siRNA26 alone (P ¼ 0.020) or siRNA28 alone (P ¼ 0.024), starting from third week onward. No significant differences were noted in terms of the body weight of the animals in any of the groups.
Immunohistopathological evaluation of xenograft tumor tissues correlate with that of in vitro and in vivo observations
Ki-67 index in siRNA26+28 combination-treated group was 16 ± 15(P ¼ 0.001), whereas it was 37 ± 18(P ¼ 0.001) and 28±11(P ¼ 0.02) for siRNA26-treated and siRNA28-treated groups in comparison with control-siRNAtreated animals (Figures 6a-d) . However, no statistically significant differences were observed between siRNA26-and siRNA28-treated groups with that of combination (siRNA26+28)-treated animals in terms of Ki-67 antigen expression by immunohistochemistry.
Discussion
AURKB and EGFR are commonly amplified and overexpressed genes in various types of cancers, including hormone refractory prostate cancer. 8, 9 Here in this report, we tested our hypothesis that knockdown of either AURKB or EGFR may cause inhibition of cancer cell proliferation because of apoptosis induction, whereas their combination may have synergic effect as depicted Figure 7 Schematic representation in which the transfection of hormone refractory prostate cancer cells led to synergic effect when treated with siRNA26 and 28. Knockdown of EGFR leads to inhibition of tyrosine kinases and thus decrease in S-phase of cell cycle resulting in arrest of cells at G1 phase. Knockdown of AURKB results in failure in cytokinesis and thus accumulation of cells in G2 phase of cell cycle leading to polyploidy. Thus, the inhibition of both EGFR and AURKB pathways results in dysregulation of cell cycle leading to activation of apoptotic mechanisms. X represents knockdown action.
Cell cycle deregulation
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MK Addepalli et al in Figure 7 . We were able to achieve almost complete suppression of AURKB and EGFR expression using siRNA treatment strategy in both hormonal refractory as well as hormone-sensitive prostate cancer cells. Knockdown of AURKB and EGFR induced strong suppression of growth and eventual apoptosis in hormone refractory prostate cancer cells in a dose-dependent manner, either alone or in combination. But in hormone-sensitive prostate cancer cell line, LNCaP, both AURKB and EGFR siRNA have shown inhibition of cancer cell proliferation and apoptotic induction at relatively higher concentrations than in PC3 cells. In addition, the CI values show synergistic effect in hormone refractory prostate cancer cells, whereas this was found to be antagonistic in hormonal-sensitive cell line, LNCaP. These results indicate that higher the expression levels of AURKB and EGFR, greater the inhibition in cancer cell proliferation and apoptosis when knocked down by siRNA. The observed antagonistic behavior in LNCaP cells may be attributed to competitive inhibition by siRNA26 and siRNA28 for RNAi machinery. This is also evident from our protein blot analysis in which the quantity of protein being knocked down is lower during combination treatment over individual siRNA treatments ( Figure 1 ) for both AURKB and EGFR. Although competitive inhibition is observed in PC3 cells too, synergism was also observed in PC3 cells, as they are highly susceptible to any decrease in the expression levels of either AURKB or EGFR. Similar results are reported earlier by Wilkinson et al. 13 in which treatment of cells with AURKB inhibitor, AZD1152, led to failure of cell division, causing accumulation of cells in 4N followed by induction of apoptotic cell death. EGFR-driven signaling not only controls cancer cell proliferation, but also is responsible for tumor progression, including apoptosis, invasion, and angiogenesis. 14 The inhibition of EGFR was found to cause reduction in cell growth and stimulation of apoptosis.
11 Thus, the enhanced therapeutic efficacy in inhibition of cancer cell proliferation, colony formation, and apoptosis induction achieved by treating with combination of AURKB and EGFR siRNA may be attributable to their respective signaling pathways as shown in Figure 7 . In addition, administration of AURKB and EGFR siRNA alone has resulted in suppression of prostate xenograft tumor. These results suggest that the overexpression of AURKB and EGFR are associated with the in vivo tumorigenic ability of prostate cancer cells, leading us to expect that a knockdown strategy will be practical in stopping the progression of the cancer in vivo.
Most current cancer treatments are combinations of chemotherapeutic agents, and it is expected that newer targeted drugs achieve their greatest efficacy in combination with traditional cytotoxic agents. Recently, a number of studies 10, 11, 15 explored the possibility of combining relatively specific drug molecules (tyrosine kinase inhibitors) with traditional chemotherapeutic agents (Taxanes, platinum, etc.) to sensitize the cancer cells toward chemotherapeutic drugs enhancing, cytotoxic properties. Here, in this study, we showed that the RNAi-mediated knockdown of AURKB in combination with EGFR shows enhanced therapeutic efficacy in which 40% of the treated animals were found to be tumor free.
The overexpression of EGFR is associated with resistance to cytotoxic drugs and is generally an indicator of poor prognosis. [16] [17] [18] For this reason, several approaches, including usage of monoclonal antibodies and pharmacological inhibitors of EGFR tyrosine kinase, have been used. Effectiveness of most of these inhibitors is found to be limited because of their ability to block only the phosphorylating activity of the receptor, but not glucose transportation functions. 19 Therefore, to overcome these limitations and obtain synergistic therapeutic efficacy, tyrosine kinase inhibitors were administered in association with the traditional chemotherapeutic drugs. 20 However, cytotoxic drugs are known to be highly toxic in nature and may cause various side effects in addition to development of drug resistance if used over a prolonged period of time. 21 Furthermore, radiation treatment is known to cause overexpression of EGFR as a compensatory mechanism to repopulate. To counter this in head and neck cancers, radiation therapy is administered in combination with anti-EGFR inhibitors to derive additive effect. 22 The additive effect observed is due to accumulation of cells in G2 phase of cell cycle by radiation treatment, whereas anti-EGFR inhibitors cause G1 arrest. In our study, AURKB knockdown also causes G2 accumulation of cells, whereas EGFR knockdown lead to increased apoptosis resulting in enhanced therapeutic effect in hormone refractory prostate cancer cells.
These results implicate that simultaneous knockdown of both AURKB and EGFR in hormonal refractory prostate cancer is a promising therapeutic approach, which needs to be explored further on detailed mechanisms of action.
Materials and methods
Cell lines
The human prostate cancer cell lines, PC3 and LNCaP, were obtained from American Type Culture Collection, Manassas, VA, USA and cultured in a humidified atmosphere of 5% CO 2 at 37 1C as per their instructions. Subconfluent cultures (60-70% confluent) not exceeding 10 passages were used in experiments.
siRNA transfections
The mRNA sequences for human aurk B (Gene bank Accession No. NM_004217) and human egfr (Gene bank Accession No. NM_005228) were used to design siRNAs targeting AURKB and EGFR, respectively. Three doublestranded siRNAs for each targeting genes AURKB and EGFR were custom synthesized through Qiagen (Hilden, Germany) along with control-siRNA against EGFP (Supplementary Table 1 ). Transfections with 10 nM siRNA concentration were performed for all experiments unless otherwise stated specifically using Hiperfect transfection reagent (Qiagen) as per the manufacturer's instructions.
The transfection efficiency in PC3 and LNCaP cell lines was determined using Cy3-labeled control-siRNA (control-siRNA was labeled with Cy3 using Silencer siRNA-labeling kit-Cy3 from Ambion, Austin, TX, USA following manufacturer's instructions).
Quantitative real-time PCR
First strand cDNA was prepared from siRNA-transfected PC3 cells using Fast cell cDNA kit (Qiagen) as per manufacturer's instructions. Quantitative real-time PCR was performed using the Applied Biosystems 7500 system (ABI, Foster city, CA, USA) and data analyzed AURKB-EGFR knockdown shows enhanced therapeutic efficacy MK Addepalli et al as per the instructions of the manual. The abundance of mRNA was measured by real-time quantitative PCR at 72 h post-transfection for screening siRNAs designed. The efficacy of most potent siRNA was determined at different time points ranging from 48 to 96 h. b-actin was used as the internal reference control. All primers and probes were represented in Supplementary Table 2 .
Evaluation of interferon response by siRNA under in vitro conditions
The effect of siRNA26 or siRNA28 to stimulate interferon response was analyzed at the end of 20 h post-transfection in both PC3 and LNCaP cells. Interferon response was detected by gene expression analysis using Interferon response detection kit (SI300A-1, SBI system Biosciences, Mountain view, CA, USA) following manufacturer's instructions. All the experiments were performed thrice, from independent transfections, and their average values were presented.
Immunoblotting
Protein lysates were prepared from siRNA-transfected cells (after 72 h) in Mammalian Protein Extraction Reagent (Pierce, Rockford, IL, USA) and protein content of the lysate was estimated using the Bradford reagent (Bio-Rad, Hercules, CA, USA). Equal amounts of protein were loaded and western blot analysis was carried out as described earlier 23 using polyclonal antibody to AURKB (A5102, Sigma, St Louis, MO, USA) and monoclonal anti-EGFR antibody (E2760, Sigma). Monoclonal antibody against a-tubulin-clone DM1A (T6199, Sigma) was used to detect a-tubulin, as an internal control. Goat antimouse IgG (g-chain specific)-alkaline phosphatase (A3438, Sigma) was the secondary antibody used. All protein blots were repeated three times from independent transfections and their s.d. were determined from densitometric analysis.
CI determination
The cell lines, PC3 and LNCaP, were transfected with siRNA as described earlier, using five concentrations at one log increment each (0.01, 0.1, 1, 10, and 100 nM). After 72 h of transfection, floating and adherent cells were collected. The cells were stained with 0.4% trypan blue solution and the viable and non-viable cells were counted using Neubauer's chamber.
The IC 50 values were obtained from concentrationeffect curves for single agents as well as for combination following CI method. 24 All the experiments were repeated thrice from independent transfections and their s.d. was determined while plotting concentration-effective curves.
Apoptosis assay
Knockdown effect of AURKB, EGFR, and their combination on apoptosis was determined at various time points starting from 24 to 120 h for every 24 h interval posttransfection in PC3 and LNCaP cell lines. Apoptotic cell death was determined using the Cell Death Detection ELISA kit (Roche, Mannheim, Germany), following manufacturer's instructions. Absorbance was measured at 405 nm (reference wavelength, 490 nm) using a Biotek spectrophotometer plate reader (Biotek, Winooski, VT, USA). All the experiments were performed in triplicates and the P-values compared between control-siRNA treated and siRNA26 (AURKB), siRNA28 (EGFR), or their combination (AURKB+EGFR) treatments, respectively. Furthermore, P-values were also compared between siRNA26+28 and siRNA26/28 to determine the enhanced therapeutic effect over individual treatments.
Soft agar assay for colony formation
Soft agar colony assay was performed as described earlier 25 with minor modifications. Twenty-four hours post-siRNA transfection, PC3 cells were plated at a concentration of 500 cells per well in six-well plates and incubated at 37 1C, 5% CO 2 atmosphere. After 10 days of incubation, the resultant colonies were stained with 0.005% crystal violet and counted manually. All the experiments were performed in triplicate and their P-values determined.
In vivo efficacy
PC3 cells grown in RPMI1640 with 10% fetal bovine serum were harvested and resuspended in saline at 10 million cells 0.1 ml À1 volume. Athymic nude mice (NIH strain) were injected with 0.1 ml of the cell suspension subcutaneously on the flank and observed daily for tumor appearance. Tumors were measured in two dimensions (width Â length) to assess tumor growth using digital calipers. Tumor volumes were calculated using the equation (a Â b 2 )/2, where a ¼ largest diameter and b ¼ smallest diameter, and expressed as group mean±s.d. When the tumors attained a volume of B50-60 mm 3 , they were randomized into four groups, namely, siRNA26 treated (n ¼ 7), siRNA28 treated (n ¼ 3), siRNA26+28 (n ¼ 5) treated, and control-siRNA (n ¼ 6) treated. For all groups, siRNA complexed with the transfection reagent, Hiperfect, was administered at 1 mg kg À1 body weight once every week for 4 weeks, intratumorally. After 72 h of the first dosage, tumors were retrieved from the siRNA26-treated group (n ¼ 2) and the control-siRNA-treated group (n ¼ 1) to analyze for AURKB protein knockdown levels by immunoblot analysis. During the course of the treatment, remaining animals were observed everyday for clinical signs and tumor volumes were measured every third day. At the end of 5 weeks, the animals were killed and the tumors fixed in 10% formalin and embedded in paraffin for further immunohistopathological studies. All experiments involving mice were approved by the Committee for the Purpose of Supervision and Control of Experiments on animals (CPCSEA), India.
Determination of the Ki-67-labeling index
The expression of Ki-67, a cellular marker for proliferation, in PC3 tumor tissues treated with siRNA26 and siRNA28, either alone or in combination, was evaluated by immunohistochemistry as described earlier. 26 Anti-Ki-67 antigen monoclonal antibody was diluted 1:200 (P6834, Sigma) and incubated with the sections at 4 1C overnight. Biotinylated goat antibody to mouse/rabbit IgG (Dakocytomation, Carpinteria, CA, USA) was used as the secondary antibody. The sections were developed using liquid DAB-substrate chromogen system (Dako) and counterstained with hematoxylin (Sigma). One thousand cells for each slide were examined at Â 100 magnification under Nikon Eclipse 80i (Tokyo, Japan).
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